GlaxoSmithKline has terminated 11 projects over the past 12 months. The respiratory franchise bore the brunt of the cuts at a time when some GSK staff were questioning the wisdom of investing in the field.
Almost half of the terminations affect respiratory drugs that advanced as far as phase 2 studies before being deemed surplus to requirements.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,